{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:52:43Z","timestamp":1785527563171,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Peking University Medicine Seed Fund for Interdisciplinary Research","award":["BMU2021MX003"],"award-info":[{"award-number":["BMU2021MX003"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2020-20-34"],"award-info":[{"award-number":["320.6750.2020-20-34"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00280-022-04484-6","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T15:03:27Z","timestamp":1666451007000},"page":"489-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic\u2013pharmacodynamic model of neutropenia"],"prefix":"10.1007","volume":"90","author":[{"given":"Weizhe","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-2982","authenticated-orcid":false,"given":"Tianyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"key":"4484_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et\u00a0al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4484_CR2","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1158\/1078-0432.Ccr-16-0493","volume":"22","author":"AJ Walker","year":"2016","unstructured":"Walker AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, Tang S et\u00a0al (2016) FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 22:4968\u20134972. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0493","journal-title":"Clin Cancer Res"},{"key":"4484_CR3","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.Ccr-15-1185","volume":"21","author":"JA Beaver","year":"2015","unstructured":"Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T et\u00a0al (2015) FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 21:4760\u20134766. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1185","journal-title":"Clin Cancer Res"},{"key":"4484_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/annonc\/mdx365.054","volume":"28","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V, Harbeck N, Joy AA (2017) PALOMA-2: neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER+)\/human epidermal growth factor receptor 2-negative (HER2\u2013) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P + L). Ann Oncol 28:291","journal-title":"Ann Oncol"},{"key":"4484_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/jgo.2016.008318","volume":"3","author":"H Iwata","year":"2017","unstructured":"Iwata H, Im SA, Masuda N, Im YH, Inoue K et\u00a0al (2017) PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients. J Glob Oncol 3:289\u2013303. https:\/\/doi.org\/10.1200\/jgo.2016.008318","journal-title":"J Glob Oncol"},{"key":"4484_CR6","unstructured":"Inc, F. (2015) IBRANCE\u00ae (palbociclib): US prescribing information."},{"key":"4484_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discovery 14:130\u2013146. https:\/\/doi.org\/10.1038\/nrd4504","journal-title":"Nat Rev Drug Discovery"},{"key":"4484_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia. Cancer 100:228\u2013237. https:\/\/doi.org\/10.1002\/cncr.11882","journal-title":"Cancer"},{"key":"4484_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00280-021-04263-9","volume":"88","author":"B Xu","year":"2021","unstructured":"Xu B, Li H, Zhang Q, Sun W, Yu Y et\u00a0al (2021) Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+\/HER2\u2212 advanced breast cancer in Chinese women. Cancer Chemother Pharmacol 88:131\u2013141. https:\/\/doi.org\/10.1007\/s00280-021-04263-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"4484_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00173","volume":"5","author":"SA Im","year":"2019","unstructured":"Im SA, Mukai H, Park IH, Masuda N, Shimizu C et\u00a0al (2019) Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol 5:1\u201319. https:\/\/doi.org\/10.1200\/JGO.18.00173","journal-title":"J Glob Oncol"},{"key":"4484_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11523-020-00771-5","volume":"16","author":"J Zheng","year":"2021","unstructured":"Zheng J, Yu Y, Durairaj C, Di\u00e9ras V, Finn RS et\u00a0al (2021) Impact of dose reduction on efficacy: implications of exposure\u2013response analysis of palbociclib. Target Oncol 16:69\u201376. https:\/\/doi.org\/10.1007\/s11523-020-00771-5","journal-title":"Target Oncol"},{"key":"4484_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4143\/crt.2020.451","volume":"53","author":"J Lee","year":"2021","unstructured":"Lee J, Park HS, Won HS, Yang JH, Lee HY et\u00a0al (2021) Real-world clinical data of palbociclib in Asian metastatic breast cancer patients: experiences from eight institutions. Cancer Res Treat 53:409\u2013423. https:\/\/doi.org\/10.4143\/crt.2020.451","journal-title":"Cancer Res Treat"},{"key":"4484_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10928-006-9035-z","volume":"34","author":"P Jacqmin","year":"2007","unstructured":"Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P et\u00a0al (2007) Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K\u2013PD model. J Pharmacokinet Pharmacodyn 34:57\u201385. https:\/\/doi.org\/10.1007\/s10928-006-9035-z","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4484_CR14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/jcph.902","volume":"57","author":"W Sun","year":"2017","unstructured":"Sun W, O\u2019Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI et\u00a0al (2017) Characterization of neutropenia in advanced cancer patients following palbociclib treatment using a population pharmacokinetic\u2013pharmacodynamic modeling and simulation approach. J Clin Pharmacol 57:1159\u20131173. https:\/\/doi.org\/10.1002\/jcph.902","journal-title":"J Clin Pharmacol"},{"key":"4484_CR15","unstructured":"Yanke Yu, D. W. (2019) Population pharmacokinetics and exposure\u2013response of neutropenia: analyses in first-line patients with advanced breast cancer with palbociclib treatment. American College of Clinical Pharmacology Annual Meeting. Chicago, IL, USA"},{"key":"4484_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/jcph.1971","volume":"62","author":"Y Yu","year":"2022","unstructured":"Yu Y, Sun W, Liu Y, Wang D (2022) Pharmacodynamic modeling of CDK4\/6 inhibition-related biomarkers and the characterization of the relationship between biomarker response and progression-free survival in patients with advanced breast cancer. J Clin Pharmacol 62:376\u2013384. https:\/\/doi.org\/10.1002\/jcph.1971","journal-title":"J Clin Pharmacol"},{"key":"4484_CR17","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2002","unstructured":"Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713\u20134721. https:\/\/doi.org\/10.1200\/JCO.2002.02.140","journal-title":"J Clin Oncol"},{"key":"4484_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","volume":"33","author":"AF van der Meer","year":"2011","unstructured":"van der Meer AF, Marcus MA, Touw DJ, Proost JH, Neef C (2011) Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit 33:133\u2013146. https:\/\/doi.org\/10.1097\/FTD.0b013e31820f40f8","journal-title":"Ther Drug Monit"},{"key":"4484_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC et\u00a0al (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395:817\u2013827. https:\/\/doi.org\/10.1016\/S0140-6736(20)30165-3","journal-title":"Lancet"},{"key":"4484_CR20","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/pharmaceutics13101708","volume":"13","author":"AL Marouille","year":"2021","unstructured":"Marouille AL, Petit E, Kaderbha\u00ef C, Desmoulins I, Hennequin A et\u00a0al (2021) Pharmacokinetic\/pharmacodynamic model of neutropenia in real-life palbociclib-treated patients. Pharmaceutics 13:1708","journal-title":"Pharmaceutics"},{"key":"4484_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030181","author":"B Royer","year":"2021","unstructured":"Royer B, Kaderbhai C, Fumet JD, Hennequin A, Desmoulins I et\u00a0al (2021) Population pharmacokinetics of palbociclib in a real-world situation. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14030181","journal-title":"Pharmaceuticals (Basel)"},{"key":"4484_CR22","doi-asserted-by":"crossref","unstructured":"Wan Sun, D. W. (2014) A population pharmacokinetic analysis of palbociclib (PD-0332991) in patients with advanced cancer. European Society for Medical Oncology 2014 Congress","DOI":"10.1093\/annonc\/mdu331.22"},{"key":"4484_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/clpt.1994.155","volume":"56","author":"WJ Jusko","year":"1994","unstructured":"Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406\u2013419. https:\/\/doi.org\/10.1038\/clpt.1994.155","journal-title":"Clin Pharmacol Ther"},{"key":"4484_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427\u2013437. https:\/\/doi.org\/10.1634\/theoncologist.10-6-427","journal-title":"Oncologist"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04484-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T10:09:30Z","timestamp":1667642970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04484-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4484"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04484-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,22]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conficts of interest in relation to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}